151 related articles for article (PubMed ID: 2926141)
1. Functional heterogeneity of macrophage precursor cells from spleen of Leishmania donovani-infected and untreated mice.
Hockertz S; Baccarini M; Lohmann-Matthes ML
J Immunol; 1989 Apr; 142(7):2489-94. PubMed ID: 2926141
[TBL] [Abstract][Full Text] [Related]
2. Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani.
Reiner NE
J Immunol; 1987 Mar; 138(6):1919-25. PubMed ID: 3493291
[TBL] [Abstract][Full Text] [Related]
3. In vitro natural cell-mediated cytotoxicity against Candida albicans: macrophage precursors as effector cells.
Baccarini M; Bistoni F; Lohmann-Matthes ML
J Immunol; 1985 Apr; 134(4):2658-65. PubMed ID: 3882833
[TBL] [Abstract][Full Text] [Related]
4. Isolation of protective T cells from BALB/cJ mice chronically infected with Leishmania donovani.
Holaday B; Sadick MD; Pearson RD
J Immunol; 1988 Sep; 141(6):2132-7. PubMed ID: 3262649
[TBL] [Abstract][Full Text] [Related]
5. Organ-associated macrophage precursor activity: isolation of candidacidal and tumoricidal effectors from the spleens of cyclophosphamide-treated mice.
Baccarini M; Bistoni F; Lohmann-Matthes ML
J Immunol; 1986 Feb; 136(3):837-43. PubMed ID: 3079800
[TBL] [Abstract][Full Text] [Related]
6. IL-2-stimulated splenocytes reduce infections by Leishmania donovani in vivo.
Olivier M; Eslami Z; Tanner CE
J Parasitol; 1996 Feb; 82(1):78-81. PubMed ID: 8627506
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of 3H-thymidine-prelabelled Leishmania donovani amastigotes and promastigotes to the cytotoxic activity of peritoneal, splenic and liver macrophages.
Hockertz S; Emmendörffer A; Lohmann-Matthes ML
Immunobiology; 1989 Jun; 179(2-3):202-13. PubMed ID: 2793202
[TBL] [Abstract][Full Text] [Related]
8. Intracellular destruction of Leishmania donovani and Leishmania tropica amastigotes by activated macrophages: dissociation of these microbicidal effector activities in vitro.
Hockmeyer WT; Walters D; Gore RW; Williams JS; Fortier AH; Nacy CA
J Immunol; 1984 Jun; 132(6):3120-5. PubMed ID: 6725948
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of leishmanicidal activity of human macrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte macrophage colony stimulating factor.
Al-Zamel F; Al-Shammary FJ; El-Shewemi S; Soliman R
Zentralbl Bakteriol; 1996 Sep; 285(1):92-105. PubMed ID: 8946701
[TBL] [Abstract][Full Text] [Related]
10. A role for oxygen-dependent mechanisms in killing of Leishmania donovani tissue forms by activated macrophages.
Haidaris CG; Bonventre PF
J Immunol; 1982 Aug; 129(2):850-5. PubMed ID: 6282971
[TBL] [Abstract][Full Text] [Related]
11. Alteration of Leishmania donovani infection levels by selective impairment of macrophage signal transduction.
Moore KJ; Labrecque S; Matlashewski G
J Immunol; 1993 May; 150(10):4457-65. PubMed ID: 8482844
[TBL] [Abstract][Full Text] [Related]
12. Antibody-dependent cellular cytotoxicity against tumor cells. II. The promonocyte identified as effector cell.
Domzig W; Lohmann-Matthes ML
Eur J Immunol; 1979 Apr; 9(4):267-72. PubMed ID: 467490
[TBL] [Abstract][Full Text] [Related]
13. Innate immune defense in visceral leishmaniasis: cytokine mediated protective role by allogeneic effector cell.
Manna PP; Chakrabarti G; Bandyopadhyay S
Vaccine; 2010 Jan; 28(3):803-10. PubMed ID: 19879234
[TBL] [Abstract][Full Text] [Related]
14. Comparative susceptibility of African green monkeys (Cercopithecus aethiops) to experimental infection with Leishmania leishmania donovani and Leishmania leishmania infantum.
Binhazim AA; Shin SS; Chapman WL; Olobo J
Lab Anim Sci; 1993 Feb; 43(1):37-47. PubMed ID: 8459677
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine mediated microbicidal activity of peritoneal macrophages from Leishmania donovani infected and drug treated BALB/c mice.
Sodhi S; Ganguly NK; Malla N; Mahajan RC
Jpn J Exp Med; 1989 Jun; 59(3):103-8. PubMed ID: 2554031
[TBL] [Abstract][Full Text] [Related]
16. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
17. rIL-2-stimulated splenocytes reactivate the NO2-producing ability of macrophages infected by Leishmania donovani.
Eslami Z; Tanner CE
Immunopharmacol Immunotoxicol; 2000 Aug; 22(3):465-87. PubMed ID: 10946826
[TBL] [Abstract][Full Text] [Related]
18. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
Murray HW; Delph-Etienne S
J Infect Dis; 2000 Feb; 181(2):795-9. PubMed ID: 10669380
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
Sarkar K; Das PK
J Immunol; 1997 Jun; 158(11):5357-65. PubMed ID: 9164956
[TBL] [Abstract][Full Text] [Related]
20. Mast cells at the host-pathogen interface: host-protection versus immune evasion in leishmaniasis.
Saha B; Tonkal AM; Croft S; Roy S
Clin Exp Immunol; 2004 Jul; 137(1):19-23. PubMed ID: 15196239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
